China's Health Ministry on Tuesday urged medical institutes nationwide to step up management of clinical use for the blood-thinner heparin, and to boost surveillance and reports of heparin-related medical incidents.
The ministry said in a statement it had received reports from the State Food and Drug Administration that heparin products had caused serious reactions and even deaths in the United States. Rawheparin produced and exported by some companies in China was involved.
The ministry requested medical facilities nationwide to strictly check the medicine they sourced and make sure the origin could be traced later. Doctors must strictly follow relevant regulations when applying heparin products to ensure safety.
Medical institutions must also strengthen management of patients who receive heparin treatment and closely observe and keep a good record of them, the ministry said. Any suspected adverse cases must be dealt with immediately and reported.
Typical symptoms of a reaction to heparin include lip swelling, nausea, vomiting, sweating, shortness of breath and sometimes severely low blood pressure.
Source: Xinhua
|
Comment
Tell A Friend
Print Format
Save Article